Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.71%
1,092.80
-7.77
-0.71%
—1,100.571,098.941,103.801,084.24——
SIXC
Communications
SIXC
Communications
SIXC
-0.07%
604.74
-0.41
-0.07%
—605.15605.15606.69602.76——
SIXE
Energy
SIXE
Energy
SIXE
+1.64%
1,214.80
+19.61
+1.64%
—1,195.191,204.711,221.691,204.71——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,724.57
-15.34
-0.88%
—1,739.911,734.501,734.501,710.67——
SIXM
Financials
SIXM
Financials
SIXM
+0.14%
639.43
+0.87
+0.14%
—638.56640.21645.32638.69——
SIXR
Staples
SIXR
Staples
SIXR
+0.91%
839.15
+7.58
+0.91%
—831.57840.48844.16834.54——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.06%
215.62
+2.26
+1.06%
—213.36213.36215.79212.77——
SIXT
Technology
SIXT
Technology
SIXT
-1.69%
3,179.52
-54.66
-1.69%
—3,234.183,171.863,195.363,145.46——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.13%
936.91
+1.26
+0.13%
—935.65937.31941.44933.16——
SIXV
Health care
SIXV
Health care
SIXV
+0.24%
1,452.77
+3.51
+0.24%
—1,449.261,454.771,462.651,447.95——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.72%
2,365.18
-17.27
-0.72%
—2,382.452,371.192,380.452,362.86——
CVM:NYSEAMERICAN
CEL-SCI Corp
$3.04
0.00%
(0.00) 1D
Apr 28, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CVM...
Mkt. cap
25.71M
Avg. vol.
45.52K
Volume
1.00
52-wk high
$13.48
52-wk low
$1.98
EPS
-$5.24
Beta
0.99
Shares outstanding
8.46M
No. of employees
43
News stories
From sources across the web
Profile
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
About CEL-SCI Corp
CEO-
Employees43
FoundedMar 1983
HeadquartersVienna, Virginia, United States
SectorBiotechnology
Websitecel-sci.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
-
-
-
-
Cost of goods sold
4.01M
3.74M
3.70M
3.68M
Cost of revenue
4.01M
3.74M
3.70M
3.68M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.38M
1.75M
2.33M
1.69M
Operating expense
2.38M
1.75M
2.33M
1.69M
Total operating expenses
6.39M
5.49M
6.03M
5.37M
Operating income
-6.39M
-5.49M
-6.03M
-5.37M
Other non operating income
-
-3.77K
60.94K
-
EBT including unusual items
-6.57M
-5.66M
-6.10M
-5.47M
EBT excluding unusual items
-6.57M
-5.66M
-6.10M
-5.46M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-6.57M
-5.66M
-6.10M
-5.47M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-178.29K
-172.05K
-128.50K
-87.79K
Net interest expenses
-178.29K
-172.05K
-128.50K
-87.79K
Depreciation and amortization charges
-
-
-
-
EBITDA
-5.42M
-4.53M
-5.51M
-4.40M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer